Figure 7: Validation of SARI in human colon cancer tissue microarray.

(a) Analysis of tissue microarrays (TMAs). Staining for SARI on TMAs containing 135 normal and malignant colon tissues. Scale bar, 100 μm. (b) Statistical analysis was performed using the GraphPad Prism 5 program to compare the relative levels of SARI between normal and malignant colon tissues (Mann–Whitney test; n=135; **P<0.01; Student’s t-test). Black triangles indicate the colon sample, and the transverse lines indicate the mean. (c) Percentage of patients with high and low expression of SARI according to tumour differentiation stage. Numbers in bars represent the percentage of patients. (n=90; **P<0.01; Student’s t-test). (d) Kaplan–Meier curve showing overall survival of patients (in percentage) with colon cancer, stratified by SARI expression (high- and low-scoring tumours). SARI expression was determined by immunohistochemistry staining and scored as described in methods. The log-rank test was used to compare differences between groups (n=90; P=0.0095; long-rank test). (e,f) Correlation analyses of SARI, VEGF, Cp and CD31 in of human malignant colon tissues from 20 patients. SARI, VEGF, CD31, Cp and HIF-1α expression levels were determined by immunohistochemistry staining and scored as described in methods (e). Scale bar, 100 μm. Pearson’s correlation coefficient (r) and P value are shown (f; n=20; Pearson analysis). (g) Model for angiogenesis inhibition by SARI through direct targeting of Cp and subsequent inactivation of the HIF-1α/VEGF axis.